A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Exclusion criteria

• . Radiotherapy (except for palliative reasons), chemotherapy, endocrine therapy (with the exception of life-long hormone suppression such as luteinising hormone-releasing hormone agents in prostate cancer), immunotherapy or investigational medicinal products during the previous 4 weeks before first dose of HMBD-001 or enzalutamide, as applicable.
• . Participants with ongoing toxic manifestations of previous treatments greater than NCI CTCAE Grade 1. Exceptions apply.
• . Participants with symptomatic brain or leptomeningeal metastases should be excluded. Exceptions apply.
• . Women of child-bearing potential (or are already pregnant or lactating). Exceptions apply.
• . Male participants with partners of child-bearing potential. Exceptions apply.
• . Major surgery from which the participant has not yet recovered.
• . At high medical risk because of non-malignant systemic disease including active uncontrolled infection.
• . Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus infection. Participants with previous hepatitis C exposure but no current infection are eligible to participate.